07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Achillion, J&J deal

Achillion granted Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit exclusive, worldwide rights to develop and commercialize treatment regimens containing Achillion’s HCV assets. Achillion’s HCV pipeline includes ACH-3102, a pan-genotypic, second-generation HCV NS5A protein...
07:00 , May 25, 2015 |  BioCentury  |  Strategy

You better you bet

Johnson & Johnson's deal with Achillion Pharmaceuticals Inc. ties up one of the last remaining and most advanced unpartnered HCV portfolios and gives the pharma what could be a best-in-class molecule to catch up in...
01:55 , May 20, 2015 |  BC Extra  |  Top Story

Achillion, Janssen partner to develop HCV combo

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) granted the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to develop and commercialize treatment regimens containing Achillion's HCV assets. Achillion's HCV pipeline includes ACH-3102, a pan-genotypic,...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

ACH-3102: Additional Phase II data

Additional data from 12 treatment-naive patients with HCV genotype 1 infection in the open-label, partial-crossover Phase II proxy study showed that once-daily 50 mg ACH-3102 plus 400 mg Sovaldi sofosbuvir for 6 weeks led...
01:50 , Feb 10, 2015 |  BC Extra  |  Top Story

Achillion climbs on ACH-3102 data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $0.84 to $11.66 on Monday after it said 100% of HCV genotype 1 patients receiving ACH-3102 plus Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) achieved an SVR12 after six weeks...
08:00 , Jan 19, 2015 |  BioCentury  |  Strategy

Partitioning HCV

Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

ACH-3102: Additional Phase II data

Additional data from 12 treatment-naive patients with HCV genotype 1 infection in the open-label, partial-crossover Phase II proxy study showed that once-daily 50 mg ACH-3102 plus 400 mg Sovaldi sofosbuvir for 6 weeks led...
08:00 , Jan 5, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg1/2 clsAchillion Pharmaceuticals Inc. (NASDAQ:ACHN)BairdBrian SkorneyDowngradeNeutral (from outperform)4%$13.33 Skorney downgraded after data from a Phase I trial to treat HCV showed that ACH-3422 had slower antiviral activity than...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

ACH-3422: Interim Phase I data

Interim data from treatment-naïve patients with HCV genotype 1 infection in a double-blind, placebo-controlled Phase I trial showed that once-daily 700 mg oral ACH-3422 led to a mean maximal reduction in HCV RNA levels of...
02:32 , Dec 30, 2014 |  BC Extra  |  Top Story

Biotech stocks recovering from Bloody Tuesday

The BioCentury 100 and the NYSE Arca Biotechnology (BTK) indexes both edged up for a third day on Monday after dropping last week in the fallout from news that Express Scripts Holding Co. (NASDAQ:ESRX) had...